Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 10, 2017, Pages 2699-2704

  Sardi, S Pablo ^a   Viel, Catherine ^a   Clarke, Jennifer ^a   Treleaven, Christopher M ^a   Richards, Amy M ^a   Park, Hyejung ^b   Olszewski, Maureen A ^b   Dodge, James C ^a   Marshall, John ^a   Makino, Elina ^b   Wang, Bing ^b   Sidman, Richard L ^c   Cheng, Seng H ^a   Shihabuddin, Lamya S ^a  

^a SANOFI   (France)

^b Analytical Development   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Gaucher disease; GBA mutations; Glucosylceramide synthase; Lewy body dementia; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CERAMIDE GLUCOSYLTRANSFERASE; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; GLUCOSYLCERAMIDE; GZ 667161; TAU PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG; ENZYME INHIBITOR; GLUCOSYLTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME INHIBITION; GAUCHER DISEASE; HIPPOCAMPUS; MEMORY DISORDER; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; SYNUCLEINOPATHY; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PROTEINOSIS;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; GLUCOSYLTRANSFERASES; HUMANS; MICE; MUTATION; PARKINSON DISEASE; PROTEIN AGGREGATION, PATHOLOGICAL; TAU PROTEINS; UBIQUITIN;

EID: 85014699365     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1616152114     Document Type: Article

References (42)

1. Sidransky E, et al. (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361(17):1651-1661.
2. Nalls MA, et al. (2013) A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol 70(6):727-735.
3. Beavan MS, Schapira AH (2013) Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Ann Med 45(8):511-521.
4. Cilia R, et al. (2016) Survival and dementia in GBA-associated Parkinson's disease: The mutation matters. Ann Neurol 80(5):662-673.
5. Liu G, et al.; International Genetics of Parkinson Disease Progression (IGPP) Consortium (2016) Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. Ann Neurol 80(5):674-685.
6. Pastores GM, Hughes DA (2015) Gaucher Disease, eds Pagon RA, et al. (GeneReviews, University of Washington, Seattle, WA).
7. Cabrera-Salazar MA, et al. (2012) Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. PLoS One 7(8):e43310.
8. Marshall J, et al. (2016) CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease. Mol Ther 24(6):1019-1029.
9. Gegg ME, et al. (2012) Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 72(3):455-463.
10. Schapira AH, Chiasserini D, Beccari T, Parnetti L (2016) Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment. Mov Disord 31(6):830-835.
11. Gegg ME, et al. (2015) No evidence for substrate accumulation in Parkinson brains with GBA mutations. Mov Disord 30(8):1085-1089.
12. Schöndorf DC, et al. (2014) iPSC-derived neurons from GBA1-associated Parkinson'sdisease patients show autophagic defects and impaired calcium homeostasis. Nat Commun 5:4028.
13. Mazzulli JR, et al. (2011) Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146(1):37-52.
14. Sidransky E, Lopez G (2012) The link between the GBA gene and parkinsonism. Lancet Neurol 11(11):986-998.
15. Sardi SP, Cheng SH, Shihabuddin LS (2015) Gaucher-related synucleinopathies: The examination of sporadic neurodegeneration from a rare (disease) angle. Prog Neurobiol 125:47-62.
16. Rockenstein E, et al. (2016) Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease. Hum Mol Genet 25(13):2645-2660.
17. Manning-Boǧ AB, Schüle B, Langston JW (2009) Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: A biological link between Gaucher disease and parkinsonism. Neurotoxicology 30(6):1127-1132.
18. Cullen V, et al. (2011) Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol 69(6):940-953.
19. Xu YH, et al. (2011) Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab 102(4):436-447.
20. Fishbein I, Kuo YM, Giasson BI, Nussbaum RL (2014) Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation. Brain 137(Pt 12):3235-3247.
21. Sardi SP, et al. (2011) CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci USA 108(29):12101-12106.
22. Sardi SP, et al. (2013) Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc Natl Acad Sci USA 110(9):3537-3542.
23. Rocha EM, et al. (2015) Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons. Neurobiol Dis 82:495-503.
24. Alcalay RN, et al. (2012) Cognitive performance of GBA mutation carriers with early-onset PD: The CORE-PD study. Neurology 78(18):1434-1440.
25. Winder-Rhodes SE, et al. (2013) Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 136(Pt 2):392-399.
26. Brockmann K, et al. (2015) GBA-associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study. Mov Disord 30(3):407-411.
27. Oeda T, et al. (2015) Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease. Neurobiol Aging 36(12):3306-3313.
28. Lee VM, Giasson BI, Trojanowski JQ (2004) More than just two peas in a pod: Common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Trends Neurosci 27(3):129-134.
29. Dawson TM, Dawson VL (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302(5646):819-822.
30. Giasson BI, et al. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34(4):521-533.
31. Bendor JT, Logan TP, Edwards RH (2013) The function of α-synuclein. Neuron 79(6):1044-1066.
32. Galvagnion C, et al. (2016) Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of α-synuclein. Proc Natl Acad Sci USA 113(26):7065-7070.
33. McKeith IG, et al.; Consortium on DLB (2005) Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65(12):1863-1872.
34. Duda JE, et al. (2002) Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol 104(1):7-11.
35. Giasson BI, et al. (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300(5619):636-640.
36. Scott D, Roy S (2012) α-Synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis. J Neurosci 32(30):10129-10135.
37. Cremades N, et al. (2012) Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 149(5):1048-1059.
38. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA 95(11):6469-6473.
39. Galvagnion C, et al. (2015) Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation. Nat Chem Biol 11(3):229-234.
40. Woodard CM, et al. (2014) iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's disease. Cell Reports 9(4):1173-1182.
41. Tofaris GK (2012) Lysosome-dependent pathways as a unifying theme in Parkinson's disease. Mov Disord 27(11):1364-1369.
42. Cox TM, et al. (2015) Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: A phase 3, randomised, open-label, non-inferiority trial. Lancet 385(9985):2355-2362.